A recent industry report has unveiled that 3 out of 10 Canadians have turned to cannabis for pain management, highlighting a growing trend in the use of medical cannabis. Approximately 13% of the Canadian population reports using cannabis for medical purposes, with a staggering 74% of these individuals lacking formal authorization from a healthcare professional.
The findings indicate that many cannabis users self-report positive effects across a variety of health conditions. However, the report emphasizes that existing clinical evidence does not endorse the use of cannabis and cannabinoids as a first-line treatment option for most health conditions. Despite this, ongoing research is investigating the efficacy of cannabinoids in alleviating symptoms related to pain, cancer, psychiatric disorders, neurodegenerative disorders, and substance use disorders, with some studies yielding promising results.
As more Canadians seek guidance on cannabis use for medical purposes, healthcare providers play a crucial role in facilitating informed discussions. Unfortunately, research indicates that many healthcare professionals feel undertrained in this area, limiting their ability to provide comprehensive support and authorization for cannabis use among patients.
A significant contributing factor is the limited knowledge among practitioners regarding the endocannabinoid system (ECS) and its role in maintaining homeostasis and regulating various physiological processes. The ECS is a complex network of receptors and neurotransmitters that influences pain, mood, appetite, and immune responses, among other functions. Many healthcare practitioners may not fully understand how cannabinoids interact with the ECS to potentially alleviate symptoms associated with chronic pain, anxiety, and other conditions. This gap in knowledge hampers their confidence in discussing cannabis as a treatment option and may prevent patients from receiving the benefits of this emerging therapeutic avenue. Increasing educational resources on the ECS can empower healthcare providers to better support their patients’ needs.
The report advocates for increased investment in training healthcare providers, equipping them with the knowledge necessary to address patients’ questions and concerns about cannabis. By enhancing communication and understanding, healthcare professionals can better guide individuals in their medical cannabis journeys.
“Educating healthcare providers about the potential benefits and limitations of cannabis use is essential,” said Inesa Ponomariovaite, CEO of Nesas Hemp. “With the right training, providers can ensure that patients receive accurate information, enabling them to make informed decisions regarding their health.”
As research continues to explore the therapeutic potential of cannabinoids, it is imperative to create a well-informed healthcare environment that supports patient needs.Â
You can read more about the therapeutic benefits of CBDa on Nesas Hemp Blog.Â
—
This post brought to you by Atif Sharif.
Photo: iStock
